An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
Trial details
- Registry ID
- NCT04912856
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ezogabine; retigabine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEENCT04912856 | XENE | Phase 3 | Terminated | 2023-11-17Actual |
| XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyNCT04639310 | XENE | Phase 3 | Terminated | 2023-05-16Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |